$21.30
0.66% today
Nasdaq, Sep 30, 04:49 pm CET
ISIN
US86627R1023
Symbol
SMMT

Summit Therapeutics PLC Sponsored ADR Stock price

$21.16
-2.54 10.72% 1M
+1.87 9.69% 6M
+3.32 18.58% YTD
-0.74 3.38% 1Y
+20.01 1,740.00% 3Y
+17.67 505.44% 5Y
+10.76 103.46% 10Y
+10.97 107.65% 20Y
Nasdaq, Closing price Mon, Sep 29 2025
+0.21 1.00%
ISIN
US86627R1023
Symbol
SMMT
Industry

Key metrics

Basic
Market capitalization
$15.7b
Enterprise Value
$15.4b
Net debt
positive
Cash
$297.9m
Shares outstanding
742.8m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
60.6
Financial Health
Equity Ratio
89.3%
Return on Equity
-56.9%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-284.1m
EBIT
- | $-947.5m
Net Income
- | $-795.6m
Free Cash Flow
$-207.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -34.7%
EBIT
- | -349.1%
Net Income
- | -259.5%
Free Cash Flow
-112.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-0.3
Short interest
27.6%
Employees
159
Rev per Employee
$0.0
Show more

Is Summit Therapeutics PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

16x Buy
84%
2x Hold
11%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy
84%
Hold
11%
Sell
5%

Financial data from Summit Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
61% 61%
-
- Research and Development Expense 120 120
79% 79%
-
-169 -169
72% 72%
-
- Depreciation and Amortization 0.09 0.09
55% 55%
-
EBIT (Operating Income) EBIT -169 -169
72% 72%
-
Net Profit -178 -178
71% 71%
-

In millions USD.

Don't miss a Thing! We will send you all news about Summit Therapeutics PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Summit Therapeutics PLC Sponsored ADR Stock News

Neutral
Business Wire
6 days ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced the grant of inducement awards of options to purchase a collective total of up to 65,750 shares of common stock. Awards were made to eight new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Compan...
Neutral
Business Wire
6 days ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be featured as part of the Presidential Sy...
Positive
Seeking Alpha
8 days ago
While broad market performance has been robust, one striking aspect of this cycle has been the extraordinary gains in a handful of individual equities. Ten stocks in the large-cap Russell 1,000 have now advanced more than 1,000% since the start of this period. We take a look at each of these names to provide insight into the breadth of forces powering this bull market beyond the headline indices.
More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office United Kingdom
CEO Robert Zanganeh
Employees 159
Founded 2003
Website www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today